Cyclodextrin-mesoporous silica particle composites for controlled antibiotic release. A proof of concept toward colon targetingVise andre og tillknytning
2017 (engelsk)Inngår i: International Journal of Pharmaceutics, ISSN 0378-5173, E-ISSN 1873-3476, Vol. 531, nr 2, s. 595-605Artikkel i tidsskrift (Fagfellevurdert)
Abstract [en]
Cyclodextrins (CDs) and mesoporous silica particles (MSPs) have been combined as composite carriers for controlled antibiotic release. CDs were employed as "gatekeeper" agents and grafted onto MSPs to retain drug molecules inside the MSP carrier. A variety of CDs (unfunctionalized, positively charged and carboxymethylated) and three different coupling strategies (covalent binding, electrostatic adsorption and inclusion complexation) were systematically investigated for their ability to control the release of two antibiotic drugs, metronidazole and clofazimine. The drugs had significantly different physicochemical properties (metronidazole - small hydrophilic, clofazimine- large hydrophobic). We report for the first time on the encapsulation and characterization of metronidazole-loaded-MSP. Each CD coating strategy reduced the drug release rate in phosphate buffer compared to unmodified MSP (from 20% to 100% retained drug). Covalent binding and inclusion complex approaches were significantly more effective than electrostatically adsorbed CD. In particular, the novel inclusion complex based on host/guest interaction between benzyl-modified silica surface and alpha-CD proved to be very effective (60-100% retained drug amount). Using pharmaceutical manufacturing processes, our study shows that CD-MSP composites can retain both hydrophobic and hydrophilic antibiotic compounds with potential translation to triggered release formulation targeting bacterial infections in the colon and lower intestine.
sted, utgiver, år, opplag, sider
Elsevier, 2017. Vol. 531, nr 2, s. 595-605
Emneord [en]
Mesoporous silica particle, Cyclodextrin, Metronidazole, Clofazimine, Gatekeeper, Controlled drug release, Colon targeting
HSV kategori
Identifikatorer
URN: urn:nbn:se:mau:diva-3887DOI: 10.1016/j.ijpharm.2017.05.062ISI: 000413666800020PubMedID: 28554545Scopus ID: 2-s2.0-85020178625Lokal ID: 23460OAI: oai:DiVA.org:mau-3887DiVA, id: diva2:1400710
2020-02-282020-02-282024-06-17bibliografisk kontrollert